Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2023-05-24 Regulatory Filings
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings
2023-05-24 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2023, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2023. The text states that the press release is furnished as an exhibit and incorporated by reference, indicating this document itself is a current report filing rather than the full earnings release. The document length is 3508 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than containing detailed financial results or analysis. According to the rules, such filings that announce earnings results but do not contain the full financial data are classified as Earnings Release (ER).
2023-05-11 English
10-K/A
Annual Report FY 2022
2023-05-10 English
ARS
Annual Report
2023-04-28 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically titled as a 'Definitive Additional Materials' related to the proxy statement for the Annual Meeting of Stockholders. It includes information about the meeting date, voting instructions, and proposals to be voted on, such as election of directors and ratification of the auditor. It is not the proxy statement itself but additional materials related to it. The document is under 5,000 characters and primarily serves as a notice and overview of proxy materials, directing shareholders to access full materials online. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI).
2023-04-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.